Continuing Education (CE)
Continuing Education (CE)
Bayer has sponsored a variety of continuing education (CE) programs, which were developed to improve awareness and understanding of oncologic conditions.
All accredited CE/CME programs listed below were created independently by third-party providers and follow the standards set forth in the ACCME Standards for Commercial Support/Integrity and Independence in Accredited Continuing Education, or other similar accrediting organizations. Responsibility and control over selection, content, faculty, educational materials, and venue for the educational programs belong solely to the providers and/or accreditors. Bayer does not provide any guidance regarding the content or faculty for any programs receiving funding.
The list below is limited to CE programs supported by Bayer.
Last updated "April 2024".
Medical Crossfire: How Do We Implement Personalized Treatment for Colorectal Cancer in the Community?
PHYSICIANS' EDUCATION RESOURCE, LLC
1.25 (AMA)
Intended audience: Physicians
The State of Therapeutics for Colorectal Cancer: Matching Patients Needs with Current Evidence
Medscape, LLC
Intended audience: Physicians, Nurses
Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances with Modern Targeted Therapies
PVI, PeerView Institute for Medical Education Inc.
0.25 (AMA)
Intended audience: Physicians
Implementing Practice Strategies for Actionable Targets in mNSCLC – Virtual Patient Simulation With i-Human Patients by Kaplan
Kaplan North America LLC
2.5
Intended audience: Physicians, Nurses, Pharmacists, etc.
A New Era in the Treatment of Prostate Cancer: Integrating Personalized Therapies to Optimize Outcomes
National Association of Managed Care Physicians, Inc.
1.0 (AMA)
Intended audience: Physicians, Nurses, and Pharmacists
Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer—An Independent Satellite Symposium (ISS) Held in Conjunction with the 2023 American Urological Association (AUA) Annual Meeting
NL Communications, Inc
1.0 (AMA)
Intended audience: Physicians, Nurses, Pharmacists, etc.
2023 AUA ISS: Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Physicians' Education Resource, LLC
2.0 (AMA)
Intended audience: Physicians
Second Opinion: Investigators Discuss How They and Their Colleagues Apply Available Clinical Research in the Care of Patients with Prostate Cancer — An Independent Satellite Symposium (ISS) Held as an Adjunct to the 2023 ASCO Annual Meeting
NL Communications, Inc
2.25 (AMA)
Intended audience: Physicians
Integrating Data into Practice: Assessing the Latest Prostate Data from the 2023 Spring and Summer Oncology Meetings
Global Learning Collaborative, Inc.
1.0 (AMA, ACPE, and ANCC)
Intended audience: Physicians, Nurses, Pharmacists, etc.
2023 ASCO ISS – Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
Physicians' Education Resource, LLC
2.0 (AMA)
Intended audience: Physicians
Smarter. Stronger. Together Individualizing Treatment in Prostate Cancer and Addressing Health Disparities Through Education
Clinical Care Options, LLC
1.5 (AMA, ANCC, and ACPE)
Intended audience: Physicians, Nurses, and Pharmacists
Incorporating the Latest Treatment Changes in Prostate Cancer: Applying the Latest Evidence to Improve Outcomes
National Association of Managed Care Physicians, Inc.
1.0 (AMA, CMCN)
Intended audience: Physicians, Nurses
Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer
Ebix, Inc
0.5 (AMA)
Intended audience: Physicians
Medical Crossfire™: How Will Emerging Data Inform Treatment Planning for Patients with Prostate Cancer in the Community?
Physicians' Education Resource, LLC
1.5 (AMA)
Intended audience: Physicians
The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualization of Treatment
PeerVoice America Limited
1.0 (EBAC)
Intended audience: Physicians
Advancing Care in Prostate Cancer: No Longer Settling for "Enough" - Enhancing Treatment of Hormone-Sensitive Prostate Cancer
Medical Education Resources, Inc.
1.0 (AMA, ACPE, and ANCC)
Intended audience: Physicians, Nurses, Pharmacists, etc.
Advancing Nursing Practice in Prostate Cancer Management: Clinical Evidence, Novel Agents, and Patient Care
Society of Urologic Nurses and Associates
1.0 (ANCC)
Intended audience: Nurses, Nurse Practitioners
Peer to Peer Clinical Connections: Optimization of Radiopharmaceuticals in Prostate Cancer
Medscape, LLC
1.0 (AMA)
Intended audience: Physicians
Therapeutic Strategies for Patients With Hormone-Sensitive Prostate Cancer Across the Disease Continuum
Clinical Care Options, LLC
1.0 (CME/CPE/CE)
Intended audience: Physicians, Nurses, and Pharmacists
Histology-Agnostic Therapies for Solid Tumors: Experts Answer Frequently Asked Questions
Clinical Care Options, LLC
0.25 (AMA)
Intended audience: Physicians
Tissue Is Not Always the Issue: A New Era and Expanding Armamentarium of Histology-Agnostic Targeted Therapies for Solid Tumors
Clinical Care Options, LLC
1.5
Intended audience: Oncologists
Enhancing Timely Access to Care for Patients with Solid Tumor Malignancies in Federal and Public Health Settings: 9th Annual Federal Seminar Series
PRIME Education, LLC
Varying accreditation
Intended audience: Physicians, Nurses, Pharmacists, etc.
Follow Us
